Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Aug 4;7:7328. doi: 10.1038/s41598-017-06767-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

CPT1-associated indicators were significantly changed especially in early Parkinson’s disease stages. (A,B) AC(16:0)/FA(16:0) ratios of Parkinson’s disease were significantly decreased in both cohorts. *P < 0.05; ***P < 0.001 (Wilcoxon’s test). (C,D) Multiple comparisons for the ratios, AC(16:0)/FA(16:0) and carnitine/AC(16:0). The decrease of AC(16:0)/FA(16:0) ratios were mainly detected in the early stage of Parkinson's disease. *P < 0.05; ***P < 0.001 (Steel’s test). (E,F) Carnitine/AC(16:0) ratios were increased significantly in the 1^st cohort, but not significantly in the 2^nd cohort. (G,H) Carnitine/AC(16:0) ratios were significantly increased in H&Y stage I. *P < 0.05; ***P < 0.001 (Wilcoxon’s test). (I,J) Ratios of AC(8:0)/AC(16:0) and AC(14:1)/AC(16:0) in each H&Y stage. Similar increase of AC(8:0)/AC(16:0) ratio in H&Y stage I was detected, however, this was not significant in the 2^nd cohort. *P < 0.05; ***P < 0.001 (Steel’s test). Abbreviations: AC = acylcarnitine; FA = fatty acid; Error bars, S.D.